Cargando…
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
Early and effective glycemic control can prevent or delay the complications associated with type 2 diabetes (T2D). The benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming increasingly recognized and they now feature prominently in international T2D treatment recommendations...
Autores principales: | Gallwitz, Baptist, Giorgino, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276717/ https://www.ncbi.nlm.nih.gov/pubmed/34267725 http://dx.doi.org/10.3389/fendo.2021.645507 |
Ejemplares similares
-
Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021) -
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021) -
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022) -
Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019) -
Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)